Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (752)	5/7/1998 12:18:00 AM
From: Ariella	Respond to of 1491

InvestorLady shares with us this website for NASDAQ trades: nasdaqtrader.com &Quarter=1-1-1998&View.x=15&View.y=23 It gives volume data for Feb. and March. According to her, NITE, MASH and FAHN are shorters who don't care at all about keeping balanced market, just about making stock go down. Would anybody care to guess if they are some of the firms doing business for those nice folks who lent us money recently and who get to exercise their warrants at a discounted average price? --Ariella P.S. By the way, I've BEEN in the NYTimes and a front door approach to the science reporter, Ms. Gina Kolata, may not work. That story is already wrapping fish by now, and papers don't really highlight the companies, just the concept behind the drugs. On the other hand, Ari Goldman at the Times, who covers the religion beat and is Orthodox and, presumably, Israel- friendly, might be approached with a query about why the Times doesn't do an article about how come so much biotech R&D is being contracted out to Israel, why so much biotech venture capital is flowing that way, etc. He may know a reporter interested in that angle. Haim Aviv would be a great interviewee for such an article.

To: Ariella who wrote (752)	5/7/1998 9:24:00 AM
From: johnny weissman	Respond to of 1491

To: johnny weissman (741 ) From: Ariella Wednesday, May 6 1998 10:06PM ET Reply # of 757 >>Johnny -- you're being unfair to PARS. The Trout Group put this at the opening of their spring update on the website (Tamoxifen analog), even though an investor should NOT value a biotech company on pre-trial possibilities. Lotemax, Alrex, and late-stage trial HU-211are the items that should make the valuation standard for this stock. >>> Nor, Ariella, should investors help send a share from 12 to 86 $ because a drug seemed to work on a mouse. ... But I tend to agree with you-- except that info presented on a website is practically irrelevant to share price--unless the website is the only medium for releasing news. What comes down the wires and into, say, Yahoo Business News is important.